- Home
- BHVN vs TARS Comparison
BHVN vs TARS Comparison
Compare BHVN & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHVN
- TARS
- Stock Information
- Founded
- BHVN 2013
- TARS 2016
- Country
- BHVN United States
- TARS United States
- Employees
- BHVN N/A
- TARS N/A
- Industry
- BHVN Biotechnology: Pharmaceutical Preparations
- TARS Medicinal Chemicals and Botanical Products
- Sector
- BHVN Health Care
- TARS Health Care
- Exchange
- BHVN Nasdaq
- TARS Nasdaq
- Market Cap
- BHVN 1.9B
- TARS 1.7B
- IPO Year
- BHVN 2017
- TARS 2020
- Fundamental
- Price
- BHVN $16.52
- TARS $65.96
- Analyst Decision
- BHVN Strong Buy
- TARS Strong Buy
- Analyst Count
- BHVN 14
- TARS 7
- Target Price
- BHVN $49.23
- TARS $69.43
- AVG Volume (30 Days)
- BHVN 2.1M
- TARS 636.9K
- Earning Date
- BHVN 11-11-2025
- TARS 11-12-2025
- Dividend Yield
- BHVN N/A
- TARS N/A
- EPS Growth
- BHVN N/A
- TARS N/A
- EPS
- BHVN N/A
- TARS N/A
- Revenue
- BHVN N/A
- TARS $295,521,000.00
- Revenue This Year
- BHVN N/A
- TARS $137.28
- Revenue Next Year
- BHVN $2,079.03
- TARS $42.84
- P/E Ratio
- BHVN N/A
- TARS N/A
- Revenue Growth
- BHVN N/A
- TARS 254.45
- 52 Week Low
- BHVN $12.79
- TARS $38.48
- 52 Week High
- BHVN $54.98
- TARS $76.81
- Technical
- Relative Strength Index (RSI)
- BHVN 54.24
- TARS 50.79
- Support Level
- BHVN $16.30
- TARS $66.92
- Resistance Level
- BHVN $18.18
- TARS $74.83
- Average True Range (ATR)
- BHVN 1.26
- TARS 2.92
- MACD
- BHVN 0.02
- TARS -0.89
- Stochastic Oscillator
- BHVN 55.52
- TARS 2.81
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.